| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … The Lancet 393 (10183), 1819-1830, 2019 | 2834 | 2019 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 640 | 2017 |
| Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%: Randomized, double-blind phase III KEYNOTE-598 study M Boyer, MAN Şendur, D Rodríguez-Abreu, K Park, DH Lee, I Çiçin, ... Journal of Clinical Oncology, JCO. 20.03579, 2021 | 172 | 2021 |
| HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples. M Gumus, PF Yumuk, T Salepci, M Aliustaoglu, F Dane, M Ekenel, ... Journal of experimental & clinical cancer research: CR 25 (4), 515-521, 2006 | 133 | 2006 |
| Extrapulmonary small cell carcinoma: multimodality treatment results M Sengoz, U Abacioglu, T Salepci, F Eren, F Yumuk, S Turhal Tumori Journal 89 (3), 274-277, 2003 | 96 | 2003 |
| Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy HF Batirel, M Metintas, HB Caglar, G Ak, PF Yumuk, B Yildizeli, M Yuksel The Journal of thoracic and cardiovascular surgery 151 (2), 478-484, 2016 | 73 | 2016 |
| Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic … D Cabuk, G Basaran, C Celikel, F Dane, PF Yumuk, MS Iyikesici, ... Oncology 72 (1-2), 111-117, 2007 | 73 | 2007 |
| Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer U KEFELI, F Dane, PF Yumuk, A Karamanoglu, S Iyikesici, G Basaran, ... European Journal of Cancer Care 18 (2), 191-194, 2009 | 64 | 2009 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 50 | 2017 |
| Modified Glasgow prognostic score, prognostic nutritional index and ECOG performance score predicts survival better than sarcopenia, cachexia and some inflammatory indices in … B Demirelli, NA Babacan, Ö Ercelep, MA Öztürk, S Kaya, E Tanrıkulu, ... Nutrition and cancer 73 (2), 230-238, 2021 | 49 | 2021 |
| Epithelioid hemangioendothelioma with multiple organ involvement: report of two cases and review of the literature C Celikel, PF Yumuk, G Basaran, B Yildizeli, N Kodalli, R Ahiskali Apmis 115 (7), 881-888, 2007 | 39 | 2007 |
| Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey G Basaran, NS Turhal, D Cabuk, N Yurt, G Yurtseven, M Gumus, ... Medical oncology 28, 409-415, 2011 | 38 | 2011 |
| Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients RM Umar, S Apikoglu-Rabus, PF Yumuk International Journal of Clinical Pharmacy 42 (2), 652-661, 2020 | 35 | 2020 |
| What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery? M Gumus, PF Yumuk, G Atalay, M Aliustaoglu, B Macunluoglu, F Dane, ... Tumori Journal 91 (2), 168-172, 2005 | 34 | 2005 |
| Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma U Abacioglu, HB Caglar, PF Yumuk, Z Akgun, BM Atasoy, M Sengoz Journal of neuro-oncology 103, 585-593, 2011 | 30 | 2011 |
| The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients PF Yumuk, SZ Aydin, F Dane, M Gumus, M Ekenel, M Aliustaoglu, ... International journal of colorectal disease 19, 609-610, 2004 | 30 | 2004 |
| Port Needles: Do They Need to be Removed as Frequently in Infusional Chemotherapy? A Karamanoglu, FP Yumuk, M Gumus, M Ekenel, M Aliustaoglu, ... Journal of Infusion Nursing 26 (4), 239-242, 2003 | 30 | 2003 |
| Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer T Korkmaz, S Seber, K Okutur, G Basaran, F Yumuk, F Dane, T Ones, ... Biomarkers 18 (1), 88-94, 2013 | 28 | 2013 |
| GLASS: Global Lorlatinib for ALK (+) and ROS1 (+) retrospective Study: real world data of 123 NSCLC patients N Peled, R Gillis, S Kilickap, P Froesch, S Orlov, E Filippova, U Demirci, ... Lung Cancer 148, 48-54, 2020 | 26 | 2020 |
| Chordoma: a case series and review of the literature O Alan, T Akin Telli, O Ercelep, E Tanrikulu Simsek, T Basoglu Tuylu, ... Journal of Medical Case Reports 12, 1-5, 2018 | 26 | 2018 |
Nazım Serdar TurhalAnadolu Sağlık Merkezi Kocaeli TurkeyVerified email at anadolusaglik.org
